Your Omega-3s Aren't Converting. Your Genes May Be Why.

FADS1 encodes the delta-5 desaturase enzyme, which catalyzes one of the final steps in converting plant-based alpha-linolenic acid (ALA) into EPA (eicosapentaenoic acid). This enzyme sits at a critical junction in the pathway. Without adequate FADS1 activity, even if FADS2 is working perfectly, you can’t complete the conversion to the long-chain omega-3s your brain and heart need.

The rs174537 variant in FADS1, carried by roughly 30 to 40 percent of people of European ancestry, reduces delta-5 desaturase activity by 30 to 50 percent. If you carry the low-activity allele, your body converts ALA to EPA at roughly half the rate of someone with the ancestral genotype. This isn’t a small difference. It’s the difference between adequacy and deficiency despite identical dietary intake.

You experience this as persistent fatigue that improves transiently after you eat fish but returns within days. Your brain feels foggy in the afternoon. Your joints feel stiff in the morning. Your mood cycles without obvious reason. These are all signals that your EPA and DHA levels are chronically inadequate, and your conversion machinery can’t keep up with demand.

FADS2 encodes delta-6 desaturase, which catalyzes the very first enzymatic step in converting ALA into the longer-chain omega-3s. Think of it as the gate to the entire conversion pathway. If this enzyme is slow, nothing downstream happens efficiently, no matter how well-fed you are.

The rs1535 variant in FADS2, present in roughly 30 to 40 percent of the population, reduces delta-6 desaturase activity. Carrying the low-activity allele means your cells initiate the conversion cascade more slowly, leading to accumulation of ALA and depletion of EPA and DHA even when dietary ALA is adequate. The problem compounds if you also carry the FADS1 variant because both rate-limiting steps are slowed.

You notice this as subtle cognitive decline, difficulty concentrating during complex work, and a feeling that your brain is slower than it used to be. Your mood feels blunted or prone to irritability. Your joints ache after sitting still. These symptoms worsen during periods of dietary stress or sleep deprivation because your already-slow conversion pathway can’t meet the increased demand your brain and immune system are placing on omega-3 metabolism.

PPARG is not directly involved in omega-3 conversion, but it controls the expression of both FADS1 and FADS2. PPARG is a nuclear receptor that activates genes involved in fatty acid oxidation, glucose metabolism, and inflammatory resolution. When PPARG function is reduced, the entire lipid metabolism system becomes less efficient, including your ability to convert and utilize omega-3s.

Common PPARG variants, including Pro12Ala, occur in roughly 25 to 30 percent of European ancestry populations. Carrying the Ala allele increases cellular insulin sensitivity and modestly improves FADS gene expression, but the Pro12Pro genotype (wild-type) offers less metabolic flexibility for converting dietary fats when metabolic stress is high. This matters because PPARG activity is suppressed during periods of insulin resistance, high inflammation, or carbohydrate overconsumption.

You feel this as worsening omega-3 deficiency symptoms when you’re stressed, sleeping poorly, or eating a high-carbohydrate diet. Your joints stiffen more noticeably. Your mood becomes more reactive. Your cognitive clarity drops. This is because the downstream conversion of ALA to EPA and DHA slows further when PPARG isn’t being activated by your lifestyle. The same omega-3 supplementation that helped last month stops working as well when your metabolic stress rises.

APOE encodes apolipoprotein E, the primary protein responsible for packaging and transporting lipids (including omega-3 fatty acids) throughout your bloodstream and into cells. APOE determines how efficiently your body delivers EPA and DHA to tissues that need them most, especially the brain. Even if you’re absorbing omega-3s well, if your APOE variant is inefficient at transport, your cells still won’t get the omega-3s they need.

Approximately 25 percent of people carry the APOE4 allele, which is less efficient at omega-3 lipid transport compared to the APOE2 or APOE3 variants. APOE4 carriers have a documented increased risk of omega-3 deficiency at the cellular level and accelerated cognitive decline if omega-3 status is inadequate. This is particularly true if you also carry FADS variants that reduce conversion, creating a compound problem.

You experience this as brain fog that doesn’t respond to typical interventions like better sleep or more exercise. Your memory feels worse than it did five years ago. You struggle with decision-making and focus. Your mood is more volatile. These are signals that your brain isn’t getting the omega-3 support it needs for myelin maintenance and synaptic plasticity, even if you’re supplementing.

MTHFR converts dietary folate into the active form (methylfolate) that your cells use for methylation reactions. While MTHFR doesn’t directly convert omega-3s, it controls the methylation cycle, which regulates inflammation, detoxification, and the expression of genes involved in lipid metabolism, including FADS1 and FADS2. If your methylation cycle is broken, your omega-3 conversion pathway runs slowly regardless of genetic variants in FADS itself.

The MTHFR C677T variant, carried by roughly 40 percent of people of European ancestry, reduces methylfolate production by 35 to 40 percent. If you carry the C677T variant, your methylation cycle is chronically underfueled, which dampens FADS gene expression and reduces your capacity to convert plant omega-3s, even if your FADS variants are normal. This creates a hidden bottleneck: your FADS enzymes might be fine, but the cellular conditions they need to work in are suboptimal.

You notice this as a cluster of symptoms: fatigue that doesn’t respond to more omega-3 supplementation alone, brain fog, mood instability, joint pain, and slow exercise recovery. These overlap with omega-3 deficiency symptoms because the underlying problem is compound: you can’t convert omega-3s efficiently AND your cells can’t mount the inflammatory resolution response that omega-3s enable because methylation is underperforming.

VDR encodes the vitamin D receptor, the protein that allows your cells to respond to circulating vitamin D. Vitamin D is a master regulator of inflammation and immune function. If your VDR variants reduce the receptor’s sensitivity or abundance, your cells won’t respond adequately to vitamin D even if your 25-OH vitamin D levels are normal. This impairs your ability to resolve inflammation, which drives demand for omega-3s because they also function as anti-inflammatory molecules.

Common VDR variants like BsmI (rs1544410) and FokI (rs2228570), present in roughly 30 to 50 percent of the population depending on ancestry, reduce VDR sensitivity or expression. If you carry the low-sensitivity variants, your cells are chronically under-responsive to vitamin D, forcing your omega-3s to work harder to manage inflammation, leaving less omega-3 capacity for other critical functions like brain development and mood regulation.

You experience this as inflammation that persists despite supplementing with omega-3s. Your joints ache. Your skin breaks out. Your mood is reactive and anxious. You feel unwell despite good labs. This is because your cells are in a state of chronic immune activation that omega-3s alone can’t resolve without adequate vitamin D signaling. You’re asking your omega-3s to do a two-person job alone.